BTG1 and precursor B-cell acute lymphoblastic leukemia: Despite advances in genomics and clonality studies which assessed the impact of secondary genetic events (e.g. IKZF1 and BTG1 deletions) on the establishment and progression of B-ALL,20,21 changes regarding the drugs used in medical practice were discrete over the last fifty years.22